Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

FTC’s report focused on three largest PBMs ... A transformation in the PBM space will likely lead to fairer pricing and improved access to essential medications for customers, ultimately ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The Federal Trade Commission has published a report that found pharmacy benefit managers Caremark Rx LLC (CVS), Express Scripts and OptumRx marked up numerous specialty generic drugs by ...

The FTC reports that from 2017 to 2022 the three largest ... by then providing the drug to patients without the rebate the PBM can pocket the difference through spread pricing.

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...